GLP-1 Adoption Rates & Genetic Factors

Last reviewed: May 16, 2026

Last updated: May 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Approximately 9 million Americans are currently using GLP-1 receptor agonists, with prescriptions doubling from 2021 to 2023 across both diabetes and weight management indications. This rapid expansion reflects both genuine clinical efficacy and significant media attention, creating a landscape where patient questions about safety, suitability, and personalization have become increasingly important.

While population-level adoption data is valuable, individual response to GLP-1 medications varies considerably. Understanding your own genetic predispositions in key peptide pathways—not just general trends—can support a more targeted conversation with your healthcare provider about whether this treatment class aligns with your health profile and goals.

Current GLP-1 Adoption: Who Is Using These Medications and Why

GLP-1 medications are now prescribed across multiple patient populations. Approximately 7–8 million Americans use them for type 2 diabetes management, while 1–2 million use compounded or branded formulations for weight loss and metabolic health. Female patients comprise roughly 55–60% of weight management users, while diabetes patients show more balanced gender distribution.

Adoption varies by geography, insurance coverage, and access to compounding pharmacies. Urban and suburban areas report higher prescription rates, while rural regions face availability and cost barriers. Age distribution spans 25–75 years, with highest concentrations in adults aged 40–65, reflecting both diabetes prevalence and weight management interest among middle-aged populations.

GLP-1 Patient Demographics and Clinical Indications: A Multi-Purpose Medication Class

GLP-1 medications serve distinct clinical roles. Semaglutide and tirzepatide are approved for type 2 diabetes; branded semaglutide (Wegovy) and tirzepatide (Zepbound) are approved for chronic weight management in adults and some adolescents with obesity. Compounded versions from licensed 503A pharmacies offer similar active ingredients at variable dosing schedules and price points, expanding access for cost-conscious patients.

Patient Population	Primary Indication	Estimated US Users	Key Considerations
Type 2 Diabetes	Blood glucose control & cardiovascular benefit	7–8 million	Long-term treatment; insurance typically covers
Chronic Weight Management	Weight loss; metabolic improvement	1–2 million	Off-label or branded formulations; cost varies widely
Prediabetes (off-label)	Prevention and metabolic optimization	Growing segment	Limited evidence; individual provider discretion required
Cardiovascular Risk Reduction	Secondary prevention in high-risk patients	Smaller group	Increasingly recognized; studied in trial populations

Why Individual Variability Matters: Beyond Population Averages

Population statistics mask significant individual heterogeneity. Two patients with identical BMI and glucose levels may experience vastly different GLP-1 responses—ranging from minimal weight loss to dramatic metabolic improvement. This variability stems partly from genetics, partly from lifestyle, comorbidities, and medication interactions, and partly from unmeasured biological factors.

Genetic variants in the GLP-1 receptor pathway, FTO gene, and related metabolic loci influence baseline satiety signaling, insulin sensitivity, and appetite regulation. Understanding your own genetic predispositions can contextualize whether you align with the statistical 'typical' responder profile or fall into a subgroup where response patterns differ, informing more precise provider conversations.

Safety, Eligibility, and Provider-Led Decision-Making: Who Should Consider GLP-1 Treatment

GLP-1 medications are not appropriate for everyone. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe kidney disease, or active gastrointestinal conditions. Pregnancy, breastfeeding, and certain diabetic complications require careful evaluation. A qualified healthcare provider must assess individual risk–benefit ratios before initiation.

Current adoption trends reflect both appropriate clinical use and potential off-label prescribing for patients who may not meet guideline criteria. Before starting any GLP-1 medication, patients should undergo comprehensive metabolic screening, medication review, and discussion of realistic outcomes, potential side effects (nausea, constipation, pancreatitis risk), and long-term commitment, as discontinuation often leads to weight regain.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines key variants in the GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) genes—loci that influence appetite regulation and metabolic response patterns. This genetic context may help provide additional framework for understanding whether your biology aligns with typical GLP-1 responder profiles or suggests alternative considerations, though genetic predispositions do not predict exact medication response.

The genetic test reveals predispositions in peptide-signaling pathways, not pharmacogenomic drug metabolism markers. A patient with certain FTO or MC4R variants, for example, may have baseline metabolic characteristics that correlate with different response patterns in GLP-1 trials, but this information should be interpreted with a qualified healthcare provider as part of a comprehensive evaluation—never as a standalone predictor.

Combining population-level adoption data with individual genetic insights can support a more informed conversation with your provider. Rather than assuming you will respond like the statistical 'average' GLP-1 user, genetic context allows you to discuss whether your peptide-pathway predispositions suggest you may be a strong responder, moderate responder, or candidate for alternative approaches, helping tailor expectations and monitoring strategies.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral is $349/mo month-to-month, or from $279/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How does the article split roughly 9 million US GLP-1 users between diabetes and weight management?

The post estimates about 9 million Americans use GLP-1 receptor agonists overall, with 7 to 8 million for type 2 diabetes and 1 to 2 million for weight loss and metabolic health. It also reports that women make up roughly 55 to 60 percent of weight-management users while diabetes use is more evenly split. These are the article's own figures and it names no source for them.

Where does the post say GLP-1 use is concentrated geographically and by age?

It reports higher prescription rates in urban and suburban areas and more availability and cost barriers in rural regions, tying adoption to insurance coverage and access to compounding pharmacies. On age, it describes users spanning 25 to 75 years with the heaviest concentration between 40 and 65, which it attributes to diabetes prevalence and weight-management interest in middle age.

Which uses in the article's patient table are described as having limited evidence?

The table lists prediabetes as an off-label use with limited evidence where individual provider discretion is required, and cardiovascular risk reduction as a smaller group studied in trial populations. The two better-established rows are type 2 diabetes, where the article says insurance typically covers long-term treatment, and chronic weight management, where it says cost varies widely.

Why does the article argue two people with the same BMI can respond very differently?

It says population statistics mask individual heterogeneity, and that two patients with identical BMI and glucose levels can range from minimal weight loss to dramatic metabolic improvement. The post attributes that spread to lifestyle, other health conditions, medication interactions, and biological factors that go unmeasured, using it to argue against planning around an average responder.

What does the post list as reasons a GLP-1 might not be appropriate at all?

It names personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe kidney disease, and active gastrointestinal conditions as contraindications, and says pregnancy, breastfeeding, and certain diabetes complications require careful evaluation. The article also notes that stopping often leads to weight regain, so it frames the decision as a long-term commitment assessed by a provider.

Related Reading

• Do Genetic Tests Help Identify People Who Will Benefit From Glp 1 Medications
• Glp 1 Medications
• How Do Genetic Variations Impact Glp 1 Response
• Can A Dna Test Reveal If I Will Benefit From Glp 1 Medications

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.